[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dyspareunia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dyspareunia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,50,81,113,149,175,202,234,266,294,325],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100566825","biomodulation-and-rehabilitation-interventions-to-target-pelvic-health-100566825",false,"NCT06660212","Biomodulation and Rehabilitation Interventions to tarGet Pelvic Health","Is Multimodal Physiotherapy and\u002For Photobiomodulation Therapy Effective for Pain Reduction Among Those Who Experience Provoked Vestibulodynia: a Randomized Controlled Trial","BRIGHT","Inclusion Criteria:\n\n* Willing to travel to Ottawa area or Quebec City area\n* Biologically born female older than eighteen years\n* Pre-menopausal\n* Not currently pregnant or pregnancy\u002Fgiven birth in the past six months\n* Experiencing signs and symptoms consistent with provoked vestibulodynia alone or provoked vestibulodynia plus vaginismus\n\nExclusion Criteria:\n\n* gynaecologist cannot insert a single digit intravaginally and thus the participant would be unlikely able to tolerate the assessment procedures\n* other gynaecologic conditions such as lichen sclerosus, fissures, endometriosis, adenomyosis, or pelvic organ prolapse","FEMALE","18 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","This trial will provide evidence for the effective management of pain and pain-related domains among those who experience provoked vestibulodynia (PVD) using photobiomodulation (PBM) and multimodal physiotherapy (mPT) in a randomized controlled trial (RCT). PVD is the most common subcategory of vulvovaginal pain experienced during sexual and non-sexual activities, affects the psychological and sexual health of an astounding one in five Canadian women, yet access to evidence-informed management approaches is limited. We will employ four intervention groups: PBM, sham PBM (control), PBM combined with mPT, and mPT with sham PBM to evaluate the effectiveness of each approach on its own and the two approaches in combination.\n\nAmong those who experience PVD, we seek to answer:\n\n1. Relative to baseline and to sham PBM, does a 14-week intervention involving PBM, mPT, or a combination of mPT and PMB reduce vulvar pain severity reported on the Vulvar Pain Assessment Questionnaire (VPAQ)?\n2. Is a combined mPT and PBM intervention more effective than mPT or PMB alone when considering vulvar pain severity and\u002For related domains as measured through VPAQ?\n3. Are positive changes in vulvar pain severity and related domains observed following a 14-week intervention involving PBM, mPT or a combination of PBM and mPT retained at 6 months and at 1 year?\n\nSecondary objectives include determining the effectiveness of PBM, mPT, and mPT combined with PBM relative to sham PBM on: Patient Global Impression of Change (PGIC), pain sensitivity measured using provocative tests, the other domains of the VPAQ, sexual function, as well as investigating mediating effects of psychosocial variables (central sensitization index, chronic pain acceptance), gender identity, and the presence of vaginismus on patient response to mPT, PBM and mPT combined with PBM. Lastly we will monitor patient satisfaction with the interventions, adherence to the interventions, and any adverse events.",[27,28,29],"Vulvodynia","Provoked Vestibulodynia","Dyspareunia",[31,32,27,33,34,35,36],"Provoked vestibulodynia","Intervention","Double-blinded","Pelvic floor","laser","Vulvar pain","RECRUITING","2026-04-28",{"date":40,"type":41},"2026-05-05","ACTUAL",{"date":43,"type":41},"2025-03-17",{"date":45,"type":21},"2028-11",{"name":47,"class":48},"University of Ottawa","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100634477","effects-of-clinical-pilates-on-pain-and-quality-of-life-in-women-with-dyspareunia-100634477","NCT07540195","Effects of Clinical Pilates on Pain and Quality of Life in Women With Dyspareunia","The Effects of Clinical Pilates Exercises on Pain, Self-Esteem, Body Image, Depression and Quality of Life in Women With Dyspareunia","Inclusion Criteria:\n\n* Female participants aged 18-55 years\n* Sexually active\n* Willing to participate in the study\n* No communication problems\n* Experiencing dyspareunia\n\nExclusion Criteria:\n\n* Having respiratory or neurological problems\n* Being pregnant\n* History of urogenital surgery","55 Years",{"count":59,"type":21},20,[24],"The aim of this study is to investigate the effects of clinical Pilates exercises on pain, self-esteem, body image, depression, and quality of life in women with dyspareunia. The study addresses dyspareunia as a multifaceted health problem with psychological, social as well as physical implications. it evaluates the effects of pelvic floor-focused clinical Pilates interventions on physiological symptoms and psychosocial well-being. it also demonstrates this approach as effective, safe, and evidence-based method in the treatment of dyspareunia among women in Turkish society.",[29],[64,65,66,67,68,69],"Dyspareunia;","Female;","Sexual Dysfunction;","Exercise Therapy;","Quality of Life;","Depression","NOT_YET_RECRUITING","2026-04-24",{"date":73,"type":41},"2026-04-30",{"date":75,"type":21},"2026-04-06",{"date":77,"type":21},"2026-06-20",{"name":79,"class":48},"Okan University",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":80},"100631769","effectiveness-of-radiofrequency-combined-with-ultrasound-for-the-treatment-of-postpartum-dyspareunia-100631769","NCT07504991","Effectiveness of Radiofrequency Combined With Ultrasound for the Treatment of Postpartum Dyspareunia","Effectiveness of Combined Monopolar Radiofrequency and Ultrasound (BTL EXILIS ULTRA 360™) for the Improvement of Dyspareunia Caused by Postpartum Scarring in Women of Childbearing Age: A Study Protoco","Inclusion Criteria:\n\n* Women of childbearing age\n* Medical history of at least one prior vaginal delivery\n* Reported persistent pain during penetrative sexual intercourse\n* Meeting the clinical criteria for dyspareunia\n* Moderate to severe pain level, defined as a score of 4 or higher on the Visual Analogue Scale (VAS 0-10)\n* Eligible patients must demonstrate a moderate to severe pain level, defined as a VAS score of 4 or higher\n* No restriction on the time elapsed between the last delivery and the current clinical diagnosis.\n\nExclusion Criteria:\n\n* Contraindications to the study treatment. Women with any medical condition that precludes the use of the study technology\n* Non-postpartum dyspareunia","50 Years",{"count":90,"type":21},34,[24],"The objective of this community-based, non-randomized, quasi-experimental study is to assess the effectiveness of BTL EXILIS technology-based on combined radiofrequency and ultrasound-in women of childbearing age from an industrialized country with a diagnosis of dyspareunia following vaginal delivery.\n\nThe primary research question is:\n\n\\- Do patients experience a resolution of pain during sexual intercourse after completing the treatment?\n\nThe researcher will compare the level of pain during intercourse-following at least one vaginal delivery involving a tear or episiotomy-before and after exposure to the BTL Exilis treatment in the same individual.\n\nParticipants:\n\n* Assessment following childbirth with perineal involvement (tear or episiotomy) and presenting with dyspareunia.\n* Verification of fulfillment of inclusion criteria.\n* Decision on whether to undergo treatment, following a briefing by the researcher on the process and the signing of the informed consent form for study participation.\n* Follow-up assessment one and a half months after completing the treatment.",[29],[95,96,97,98,99,100,101,102,103],"vaginal delivery","dyspareunia","radiofrequency","perineum","Visual Analogue Scale","tear scar","episiotomy scar","woman","pain","2026-04-13",{"date":106,"type":41},"2026-04-16",{"date":108,"type":21},"2026-04",{"date":110,"type":21},"2026-12",{"name":112,"class":48},"Institut Investigacio Sanitaria Pere Virgili",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":137,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":146,"locationsCount":80},"100590048","changes-in-the-impact-of-genitourinary-syndrome-of-menopause-with-a-novel-nonhormonal-vulvovaginal-gel-assessed-by-proms-100590048","NCT06962345","Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.","Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs. Phase 2, Single Arm, Interventional, Longitudinal, Clinical Trial. Part of STOP GSM PROJECT.","STOPGSMP","Inclusion Criteria:\n\n* Patient has to have at least one symptom of GSM or suffer from symptoms related to vulvovaginal atrophy (as evidenced by gynecological examination with a Vaginal Health Index ≤15).\n* Patient must be postmenopausal with at least 1 year without a menstrual period.\n* Patient must consider that her quality of life is affected by GSM symptoms\n* Patient not followed due to any gynecological disease.\n* All participants must be able to understand and to fill in the self-reported questionnaires.\n\nExclusion Criteria:\n\n* Patients that do not want to fill the questionnaire, especially the questions that address sexual functioning.\n* Participants that use any oral products containing hormones or estrogen receptor modulators for the past 8 weeks, nor vaginal topical hormone products within 4 weeks, neither prescription nor non-prescription therapies for GSM, including topical vaginal non-hormonal lubricants or moisturizers for the last week.\n* Patients with history of vulvar, vaginal and\u002For cervical malignancy.\n* Patients having received radiotherapy treatment in the pelvic and\u002For genital region.\n* Patients with any type of disease that causes alteration of collagenogenesis.\n* Patients that use cytotoxic drugs leading to mucositis and alterations of tissue regeneration in the last 6 months.\n* Patients having received laser and\u002For radiofrequency treatment for handling genital atrophy or other pelvic floor dysfunctions.\n* Patients with active urinary and\u002For genital tract infection.\n* Patients with history of malignant neoplasm of the urinary system.\n* Patients with severe stress urinary incontinence (Sandvik test score equal to or greater than 8).\n* Patients with diagnosis of pelvic organ prolapse grade III or higher according to the POP-Q classification.\n* Patients with medical or surgery history that, at the investigator's discretion, does not allow participation in the study.\n* Patients with any other condition that, at the investigator's discretion, implies that the patient is unable to understand the implication of participating in the study and\u002For following the established procedures.","40 Years","70 Years",{"count":124,"type":21},80,[24],"The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the vulvovaginal area. Symptoms of vaginal atrophy will be compared before and after 8 weeks of use of the tested gel with the Day-to-Day Impact of Vaginal Aging (DIVA) PROMs questionnaire to assess changes impact of GSM symptoms.",[128,129,130,131,132,29,133,134,135,136],"Vulvar Atrophy","Vulvovaginal Signs and Symptoms","Genitourinary Syndrome of Menopause","Quality of Life","Menopause Related Conditions","Urinary Incontinence, Urgency-frequency","Sexual Function","Women´s Health","Vaginal Dryness",[130,129,138,131,139,135],"Patient Reported Outcome Measures","Day-to-Day Impact of Vaginal Ageing","2026-03-25",{"date":142,"type":41},"2026-03-30",{"date":144,"type":41},"2024-01-08",{"date":110,"type":21},{"name":147,"class":148},"Mucosa Innovations, S.L.","INDUSTRY",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100520670","pre-rehabilitation-for-female-patients-undergoing-pelvic-radiotherapy-100520670","NCT06059586","Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy","Inclusion Criteria:\n\n1. Female\n2. ≥ 18 years old at the time of informed consent\n3. Ability to provide written informed consent and HIPAA authorization\n4. Primary diagnosis of cervical, vaginal, vulvar, uterine, or anal cancer\n5. Candidate for curative pelvic radiation with external beam, with or without brachytherapy, per radiation oncologist's discretion\n\nNotes:\n\n* Can have prior and\u002For current modalities of treatment to address diagnosis including surgery and chemotherapy\n* Can receive radiation at any facility provided patient is able to perform Physical Therapy visits at IUH North\u002FSchwarz Cancer Center\n\nExclusion Criteria:\n\n1. Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and\u002For interfere with follow-up.\n2. Not a candidate for curative radiation therapy per radiation oncologist's discretion\n3. Prior radiation therapy to the pelvis\n4. Women who are pregnant or nursing",{"count":59,"type":21},[24],"The purpose of this study is to examine the feasibility of adding pre-rehabilitation pelvic health physical therapy to standard of care radiation therapy treatment plan for female patients who have been diagnosed with cervical, vaginal, vulvar, uterine, or anal cancer and are a candidate for curative pelvic radiation with external beam. Participants will receive education on using a vaginal dilator for use during treatment and complete questionnaires looking at pain and sexual function.",[29,159,160,161],"Pelvic Pain","Sexual Dysfunction","Radiation Toxicity",[163,164],"vaginal dilator","pelvic health physical therapy","2026-02-25",{"date":167,"type":41},"2026-02-27",{"date":169,"type":41},"2024-01-16",{"date":171,"type":21},"2027-06",{"name":173,"class":48},"Indiana University",3,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":49},"100612995","phase-2-use-of-topical-testosterone-and-estrogen-vs-estrogen-alone-in-vulvodynia-a-randomized-controlled-trial-100612995","NCT07260825","Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years or older\n* Patients with vulvodynia who present with pain (with vaginal penetration) rating score of 4 or greater\n\nExclusion Criteria:\n\n* Active vaginal infection\n* Pregnancy\n* Breast-feeding\n* Taking anti-androgenic medication (finasteride, dutasteride)\n* Using any other topical hormones to the vulva or vagina",{"count":182,"type":21},44,[184,185],"PHASE2","PHASE3","We are looking to see if patients using both topical testosterone and estrogen will have a greater improvement in pain with vaginal penetration compared to those using topical estrogen alone.",[27,29,188],"Lichen Sclerosus of Vulva",[190,191,192],"topical testosterone","estrogen cream","vulvodynia","2025-11-21",{"date":195,"type":41},"2025-12-03",{"date":197,"type":21},"2025-12",{"date":199,"type":21},"2026-08",{"name":201,"class":48},"TriHealth Inc.",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":209,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":80},"100570650","effectiveness-of-a-telerehabilitation-program-for-improving-sexual-function-and-reducing-pain-in-menopausal-women-100570650","NCT06710002","Effectiveness of a Telerehabilitation Program for Improving Sexual Function and Reducing Pain in Menopausal Women","Effectiveness of a Telerehabilitation Program for Improving Sexual Function and Reducing Pain in Menopausal Women With Dyspareunia: Protocol of a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Female\n* Age from 45 to 65 years.\n* Menopausal\n* Suffer dyspareunia for 3 months of evolution.\n* Willing to complete study questionnaires and informed consent study.\n\nExclusion Criteria:\n\n* Pacemaker or other types of electronic implant.\n* Thrombophlebitis.\n* Skin hypersensitivity or rejection of manual contact.\n* Active or previous treatment with chemotherapy or radiotherapy in the pelvic area.\n* Wounds or burns in the pelvic area.\n* Allergy to nickel and chromium.\n* Other pelvic floor physiotherapy treatments during the study intervention.\n* Other medical and surgical treatments in the pelvic region, such as muscle infiltrations or nerve blocks during the study intervention.\n* Surgical intervention in the pelvic area in the last 3 months.\n* Fibromyalgia.\n* Oncological processes that affect the sacrum.\n* Systemic diseases (infectious, vascular, endocrine, metabolic or neoplastic conditions).\n* Neuromuscular diseases (Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Myasthenia Gravis or spinal muscular atrophy).\n* Myelopathy and Osteomyelitis.\n* Diseases that cause alterations of the central nervous system (traumatic or vascular spinal cord injury).\n* Neurological or metabolic conditions that affect the ability to respond (Diabetes, Parkinson's disease, senile dementia, etc).\n* Serious mental disorder.","45 Years","65 Years",{"count":212,"type":21},90,[24],"The aim of this study is to analyze the effectiveness of a telerehabilitation program with respect to a face-to-face physiotherapy protocol in relation to the improvement of sexual function, the reduction of pain and the improvement of the quality of life, in the treatment of menopausal women with dyspareunia.",[216,130,29],"Menopause",[218,219,220,221,222,223,224],"Physiotherapy","Telerehabilitation","face to face treatment","female sexual function","vaginal dilators","manual therapy","capacitive resistive monopolar radiofrequency","2025-05-20",{"date":227,"type":41},"2025-05-23",{"date":229,"type":41},"2025-05-05",{"date":231,"type":21},"2026-03",{"name":233,"class":48},"Instituto Médico Tecnológico SL",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":251,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":264,"locationsCount":80},"100580670","vibrating-vs-traditional-therapy-for-treatment-of-entry-dyspareunia-100580670","NCT06840314","VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia","VIBRENT- VIBRating vs Traditional Therapy for Treatment of ENTry Dyspareunia","VIBRENT","Inclusion Criteria:\n\n* Assigned female at birth\n* Age ≥ 18 years old\n* Genito-pelvic pain\u002Fpenetration disorder (per ICD-10 diagnosis codes: F52.5 Vaginismus not due to a substance or known physiological condition, F52.6 Dyspareunia not due to a substance or known physiological condition, N94.1 Dyspareunia, N94.2 Vaginismus, N94.81 Vulvodynia)\n\nExclusion Criteria:\n\n* Current or prior use of a therapeutic vaginal device used to treat GPPPD\n* Unmanaged genitourinary syndrome of menopause\n* History of pelvic radiation\n* History of genital tract malignancy\n* History of female genital mutilation\n* History of prior surgery for prolapse or incontinence, including vaginal mesh or midurethral sling mesh\n* Silicone allergy",{"count":243,"type":21},60,[24],"The goal of this randomized controlled trial is to determine whether the use of a novel vibrating pelvic floor therapeutic device (\"Kiwi\") improves sexual function in sexually active women aged 18 and older with genito-pelvic pain and penetration disorder (GPPPD) more effectively than traditional vaginal dilators.\n\nThe main questions it aims to answer are:\n\n1. Does the use of the Kiwi device lead to higher sexual function scores compared to traditional vaginal dilators\n2. Does the Kiwi device improve sexual distress, pain, and overall symptom severity more effectively than traditional vaginal dilators?\n\nResearchers will compare the Kiwi vibrating device to traditional cylindrical vaginal dilators to assess whether the Kiwi device results in greater improvements in sexual function and symptom relief.\n\nParticipants will:\n\n* Be randomly assigned to use either the Kiwi device or traditional vaginal dilators.\n* Use the assigned device three times per week for 15 minutes per session over four weeks.\n* Complete surveys before and after the study, including assessments of sexual function, pain, and overall improvement.",[247,29,248,159,249,250],"Genito-Pelvic Pain\u002FPenetration Disorder","Vaginismus","Vestibulodynia","Vulvodynia (Chronic Vulvar Pain)",[252,96,253,254,255,221,256,192,257],"genito-pelvic pain\u002Fpenetration disorder","entry dyspareunia","vaginismus","pelvic pain","pain with sex","vestibulodynia","2025-05-16",{"date":260,"type":41},"2025-05-21",{"date":262,"type":41},"2025-03-01",{"date":231,"type":21},{"name":265,"class":48},"Medstar Health Research Institute",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":80},"100497748","assessment-of-womens-sexual-quality-of-life-after-benign-adnexal-surgery-using-vnotes-approach-100497748","NCT05761275","Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach","Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach in Comparison to Conventional Laparoscopy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged from 18 to 70 years\n* Discernment capacity with oral and written consent signed\n* Heterosexual intercourse (with vaginal penetration) within four weeks prior to inclusion in the study\n\nExclusion Criteria:\n\n* History of rectal surgery.\n* Suspected rectovaginal\u002Fretrocervical endometriosis.\n* History of brachytherapy or pelvic radiation.\n* Suspected malignancy.\n* History of severe pelvic inflammatory disease.\n* Active lower genital tract infection.\n* Pregnancy.\n* Women who do not speak fluent French or English.\n* Patients under tutelage (with or without capacity of judgement).",{"count":274,"type":21},62,[24],"Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is a recent innovation in minimally invasive surgery which has already proven its non-inferiority to conventional abdominal laparoscopy (CAL) for hysterectomy in terms of efficiency and safety. However, the investigators note a lack of medical literature and no specific randomized controlled trial (RCT) assessing women's sexual function after vNOTES for benign adnexal surgery.\n\nThe aim of this RCT is to confirm the non-inferiority of the vNOTES approach for benign adnexal pathology compared to CAL on women's sexual function. Secondary outcomes will evaluate vNOTES's efficiency, morbidity and postoperative complications compared to CAL for benign adnexal surgery. The relationship between adnexal mass morcellation\u002Faspiration and the quality of the histological analysis on surgical specimens will also be evaluated as secondary outcome.",[278,279,280,281,282,160,131,283,29,159,284],"Gynecologic Disease","Adnexal Mass","Adnexal Cyst","Sexuality","Adnexal Diseases","Pathology","Complication","2025-03-24",{"date":287,"type":41},"2025-03-27",{"date":289,"type":41},"2024-01-01",{"date":291,"type":21},"2027-04-03",{"name":293,"class":48},"Jean Dubuisson",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":301,"sex":302,"minAge":18,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":307,"conditions":308,"keywords":315,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":80},"100584618","use-of-tdcs-stimulation-in-neurological-and-gynaecological-conditions-100584618","NCT06891690","Use of TDCS Stimulation in Neurological and Gynaecological Conditions","tDCS","Neurological patients\n\nInclusion Criteria:\n\n* impairment of upper and lower limb function.\n\nExclusion Criteria:\n\n* no written consent to participate in the study.\n\nGynaecological patients\n\nInclusion Criteria:\n\n* women with selected gynaecological conditions (endometriosis, painful menstruation, dyspareunia, polycystic ovary syndrome) with no treatment other than tDCS stimulation.\n\nExclusion Criteria:\n\n* no written consent to participate in the study.",true,"ALL","90 Years",{"count":305,"type":21},300,[24],"The aim of the study is to test the effect of tDCS stimulation on upper and lower limb function in neurological patients and to reduce pain in gynaecological patients. And the impact of tDCS stimulation on patients' quality of life. Standardised questionnaires will be used for pre- and post-stimulation evaluation.",[309,310,311,312,29,313,314],"Stroke","Spinal Cord Diseases","Nerve Root Disorder","Endometriosis","Painful Menstruation","Polycystic Ovary",[316,317,103],"tDCS stimulation","quality of life",{"date":285,"type":41},{"date":320,"type":41},"2025-02-05",{"date":322,"type":21},"2025-12-31",{"name":324,"class":48},"Poznan University of Physical Education",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":333,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":80},"100551463","effects-of-photobiomodulation-on-pain-and-sexual-function-in-women-with-dyspareunia-randomized-clinical-trial-100551463","NCT06460415","Effects of Photobiomodulation on Pain and Sexual Function in Women With Dyspareunia: Randomized Clinical Trial","Inclusion Criteria:\n\n* Women, aged between 18 and 45 years classified with dyspareunia criteria, according to the guidelines of the European Association of Urology guideline (2022)2, who report pain in relationship greater than 3 on the visual numeric pain scale at the beginning of participation in the research , who present sensitivity to unidigital palpation of the pelvic muscular wall (e.g., levator ani, coccygeus, obturator) and who report feeling pain during penetration for at least 6 months.\n\nExclusion Criteria:\n\n* Women with a history of neurological or oncological diseases or bone fractures in the pelvic region, in addition to radiculopathies, decompensated heart disease or metabolic disorders, pregnant women, lactating women, women in menopause, women with difficulties in understanding written or spoken language, in use of photosensitizing drugs, who present an inflammatory condition or have used anti-inflammatories on the day of the evaluation, red flags (post-coital bleeding, abrupt unexplained weight loss, presence of a mass visible on ultrasound, macroscopic or microscopic hematuria), who have a diagnosis of painful bladder syndrome, irritable bowel syndrome, interstitial cystitis, fibromyalgia. Who have a history of spine surgery or have undergone any surgical intervention with general anesthesia in the last 120 days. Who is currently undergoing pelvic physiotherapy treatment.",{"count":332,"type":21},52,[24],"The goal of this clinical trial is to compare the effects of vulvar and intravaginal application of PBM compared to the sham group on pain and sexual function in women with dyspareunia . The main question \\[s\\] it aims to answer are:\n\n* What are the effects of vulvar and intravaginal application of photobiomodulation (PBM) compared to the sham group on the sexual function of women with dyspareunia in the immediate post-intervention moments and in follow-ups of 15, 30, 90 and 180 days?\n* What are the effects of vulvar and intravaginal application of photobiomodulation (PBM) compared to the sham group on pain in women with dyspareunia in the immediate post-intervention moments and in follow-ups of 15, 30, 90 and 180 days?\n\nParticipants will The GPBM photobiomodulation group will receive, during the 8 days of intervention, application in 8 points (4 red and 4 infrared) in the vulvar region and 8 points (4 red and 4 infrared) in the intravaginal pelvic floor region of PBM while the GS group will receive simulation application of PBM in the same number of vulvar and intravaginal points, in the same places where it was applied in the GPBM group. To see if 8 applications of photobiomodulation are really capable of reducing pain and improving sexual function in women with dyspareunia",[29,336,160],"Pain",[338,96,339,340,255],"photobiomodulation","sexual dysfunction","physiotherapy","2024-06-11",{"date":343,"type":41},"2024-06-14",{"date":345,"type":21},"2024-06",{"date":347,"type":21},"2027-08",{"name":349,"class":48},"Federal University of Health Science of Porto Alegre"]